Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

The Fanatec ClubSport GT Cockpit certainly looks the part, and the good news is that its feature set, ease of use and overall ...

Street-legal does not mean slow. These machines deliver huge horsepower, sharp aero, and massive top speeds that feel closer to race cars than daily drivers.

Carlisle's MP Julie Minns proposed legislation in Parliament tightening e-bike rules, and has now written to Business ...

CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. CSL's vaccine business volatility and slow margin recovery, especially at ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and strategic changes. Analyst John Athanasiou from Red Leaf Securities suggests CSL shares are oversold, ...

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...

A profit downgrade caused by Americans shunning vaccines, a pullback of demand in China and a decision to shelve the spin-off of Seqirus sent its share price crashing almost 17 per cent on Tuesday. Mr ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International ...

CSL has partnered with Dutch biotech VarmX to co-develop VMX-C001, a potential first-in-class treatment to restore blood coagulation in patients on FXa inhibitors. The agreement includes an upfront ...